In PepBank now:147 peptides, 6 blends and 13 other compounds97,577 study results from 17,383 studies8,473 clinical trialsUpdated
Comparing 2 peptides · Data version 308560
Swipe sideways to see every peptide.
| Peptide | Synthetic fragment Sermorelin | Synthetic analog Ipamorelin | |
|---|---|---|---|
| Identity | |||
| Kind | Synthetic fragment | Synthetic analog | |
| Area | Growth hormone axis | Growth hormone axis | |
| Evidence | |||
| Amount of evidence | 304 (plus 5 on natural levels, listed separately) | 110 | |
| Evidence level | Has results from studies in people | Has results from studies in people | |
| Safety | |||
| Safety results | 30 (30 in people) | 1 (1 in people) | |
| Status | |||
| Approval | |||
| Sport (WADA) | |||
| Registered trials | None registered2 more mention it but do not test it | 21 more mentions it but does not test it | |
Shared outcomes
From the regulatory data of each peptide.
The maker told the FDA it stopped selling the product. The FDA later found that the products were not withdrawn from sale for reasons of safety or effectiveness.
Outcome groups with study results for at least two of these peptides. Counts include only results from studies that gave the peptide. Bar length is the number of results, on one scale. The bars show how much was studied, not how large an effect was. A peptide with more studies can look stronger here without being stronger. For results, see the randomized results above.
| Outcome group | Sermorelin | Ipamorelin |
|---|---|---|
| Growth hormone and IGF-1Endocrine and hormones | 161131282 | 29 |
PepBank is a research reference. Talk to a doctor before you use any peptide.
Its most advanced trial is in phase 2. The FDA, the EMA and the other sources we use show no approval (as of 9 Oct 2026).
| PharmacokineticsPharmacology | 271665 | 1376 |
|---|
| Adverse eventsWhole body | 1717 | 11 |
|---|
| Glycemic controlMetabolic and weight | 77 | 22 |
|---|
| Pituitary hormonesEndocrine and hormones | 55 | 66 |
|---|
| Bone and jointMusculoskeletal | 22 | 1515 |
|---|
| Body weightMetabolic and weight | 312 | 99 |
|---|
| Receptor activity and mechanismEndocrine and hormones | 22 | 312 |
|---|
Each analog against its native parent, residue by residue. Substitutions, non-standard residues and modifications are marked. Calculated from the two sequences.
Sermorelin is the same as Somatorelin, human GHRH(1-44) residues 1 to 29, with 1 added group.
What is different
Ipamorelin differs from Ghrelin (human), ghrelin-28 at 5 positions.
What is different
For each outcome that two or more peptides have results for: the best result of a single randomized trial, on the same measure (the same kind of number, the same unit). When a trial has several dose arms, the cell shows the highest dose arm. The trials differ in people, length and dose, so a gap between two cells is not proof that one peptide works better.
No outcome has a randomized-trial result on the same measure for two or more of these peptides yet.
The other peptides have no randomized result on the same measure, so these results cannot be set side by side.
| Outcome | Sermorelin | Ipamorelin |
|---|---|---|
| Adverse eventsWhole bodyCompared as: value in the arm that got the peptide, in % | No comparable result 3 randomized-trial results measure it in another way or another unit. | 87.5% Any treatment-emergent adverse event Placebo: 94.8% Dose studied: 0.03-mg/kg twice dailypostoperative day 1 to 7 or hospital dischargen = 1142014 |
No comparable result
3 randomized-trial results measure it in another way or another unit.
87.5%
Any treatment-emergent adverse event
Placebo: 94.8%
Dose studied: 0.03-mg/kg twice dailypostoperative day 1 to 7 or hospital dischargen = 1142014
Registered trials, ranked by phase (late phases first), then posted results and enrollment. Status is the registry status. Study results come from published studies. Results posted at ClinicalTrials.gov are shown on each trial page.
No registered trial that tests Sermorelin found in ClinicalTrials.gov.
2 more mention it but do not test it. They only measure it or name it in their text.
2 trials · 2 completed · source ClinicalTrials.gov (opens in a new tab)
Helsinn Therapeutics (U.S.), Inc320 participantsApr 2011 to May 2014
Gastrointestinal Dysmotility
Helsinn Therapeutics (U.S.), Inc117 participantsApr 2008 to Dec 2009
Ileus
1 more mentions it but does not test it. They only measure it or name it in their text.